Ceramide Inhibition as a Treatment for Inhaled Toxin-Induced Metabolic Disorders ID: 2013-006

Technology Overview

This innovative research from Brigham Young University explores the link between inhaled toxins, such as cigarette smoke, and the onset of metabolic disorders through the lens of ceramide biosynthesis. By investigating the production of ceramides in the lungs and their systemic effects, this study aims to unveil a new therapeutic target for mitigating insulin resistance and metabolic disruptions.

Key Advantages

• Directly addresses the root cause of smoke-induced metabolic disorders
• Opens new avenues for therapeutic interventions targeting ceramide biosynthesis
• Utilizes a novel approach by focusing on lung-generated ceramides and their systemic impacts
• Employs comprehensive experimental aims, including both animal models and human studies, to validate findings

Problems Addressed

• Insulin resistance and metabolic dysfunction induced by cigarette smoke and potentially other inhaled toxins
• Lack of targeted treatments for metabolic disorders exacerbated by environmental factors
• The gap in understanding the systemic effects of lung-generated ceramides

Market Applications

• Development of new pharmaceuticals for treating smoke-induced metabolic disorders
• Preventative treatments for individuals at risk of exposure to harmful inhaled toxins
• Potential expansion into broader metabolic disorder treatments by targeting ceramide biosynthesis

Additional Information

Technology ID: 2013-006
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 13 May, 2025